Drugs / TBAJ-876
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05526911 | Jun → Sep 2022 | lung disorder, multidrug-resistant tuberculosis, pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07672405 | Jul 2026 → May 2027 expected | pulmonary tuberculosis | Global Alliance for TB Drug Development | Recruiting | No outcome recorded |
| Phase 2 | NCT06058299 | Oct 2023 → Dec 2024 overdue | pulmonary tuberculosis | Global Alliance for TB Drug Development | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04493671 Comparator | Jun 2020 → Jun 2022 | lung disorder, multidrug-resistant tuberculosis, pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-11-19 | Global Alliance for TB Drug Development | Results Phase 2 Clinical Trial Results Show Potential to Shorten TB Treatment Time tballiance.org ↗
The NC-009 trial (a pan-Phase 2 clinical trial) showed that, overall, sorfequiline had greater activity than bedaquiline. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-11-19 | Global Alliance for TB Drug Development | Phase 2 Clinical Trial Results Show Potential to Shorten TB Treatment Time tballiance.org ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBAJ-876 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04493671 ↗ |
| Known as | sorfequiline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07672405 ↗ |
| Modality | Small molecule | “TBAJ-876, a second-generation diarylquinoline with greater antimycobacterial activity” PMID 39194204 ↗ Aug 2024 |
| Route | Oral | “TBAJ-876 oral suspension, orally administered” NCT04493671 ↗ |